<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Does</title>
	<atom:link href="http://www.tapanray.in/tag/does/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Limiting FDI in Pharma is a protectionist cry: Does not benefit the common man.</title>
		<link>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man</link>
		<comments>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/#comments</comments>
		<pubDate>Sat, 08 Jan 2011 16:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[automatic]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[cry]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Limiting]]></category>
		<category><![CDATA[man. foreign]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[protectionist]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[route]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=317</guid>
		<description><![CDATA[“Protectionism is harmful” very aptly commented by Mr. Pranab Mukherjee, the Finance Minister of India, just the other day. This was in context of “recent US moves to hike visa fees and clamp down on outsourcing”. While almost at the &#8230; <a href="http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does China provide a more robust IPR environment than India?</title>
		<link>http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-china-provide-a-more-robust-ipr-environment-than-india</link>
		<comments>http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/#comments</comments>
		<pubDate>Mon, 08 Nov 2010 01:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[dispute]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[provide]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[settlement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=351</guid>
		<description><![CDATA[Soon after the Product Patent Act was reintroduced in India effective January 1, 2005, a raging global debate commenced focusing on the robustness of the Indian Patent system. Quite often, many participants in the debate continue to compare the adequacies &#8230; <a href="http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Indian Patents Act conform to Article 27 (Patentable Subject Matter) of TRIPS on the issue of ‘local working of patents’?</title>
		<link>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents</link>
		<comments>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/#comments</comments>
		<pubDate>Mon, 22 Feb 2010 01:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[27]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[conform]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[Matter]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subject]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=464</guid>
		<description><![CDATA[India is one of the signatories of TRIPS and has a national commitment on adherence to this important international agreement. It is, therefore, widely believed that the amended Indian Patents Act will be TRIPS compliant. A recent circular from CGPTD: &#8230; <a href="http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For greater transparency in the relationship between physicians and the pharmaceutical companies, does India need an Act like, proposed ‘The Physician Payment Sunshine Act’ of the USA?</title>
		<link>http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa</link>
		<comments>http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/#comments</comments>
		<pubDate>Mon, 16 Nov 2009 01:30:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[greater]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[proposed]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=724</guid>
		<description><![CDATA[As we discussed earlier, to make the pharmaceutical companies disclose and report various types of payments made to the physicians, two Senators of the United States of America, Chuck Grassley and Herb Kohl introduced a bill called ‘The Physician Payment &#8230; <a href="http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-greater-transparency-in-the-relationship-between-physicians-and-the-pharmaceutical-companies-does-india-need-an-act-like-proposed-the-physician-payment-sunshine-act-of-the-usa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
